Previous close | 24.07 |
Open | 24.09 |
Bid | 24.52 x 100 |
Ask | 24.54 x 100 |
Day's range | 24.06 - 24.63 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 1,998,685 |
Market cap | 4.15B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 8.02 |
EPS (TTM) | 3.06 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 35.55 |
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.